GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » Shares Outstanding (EOP)

Zymeworks (Zymeworks) Shares Outstanding (EOP) : 70.12 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Zymeworks Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Zymeworks's shares outstanding for the quarter that ended in Dec. 2023 was 70.12 Mil.

Zymeworks's quarterly shares outstanding increased from Sep. 2023 (67.92 Mil) to Dec. 2023 (70.12 Mil). It means Zymeworks issued new shares from Sep. 2023 to Dec. 2023 .

Zymeworks's annual shares outstanding increased from Dec. 2022 (63.06 Mil) to Dec. 2023 (70.12 Mil). It means Zymeworks issued new shares from Dec. 2022 to Dec. 2023 .


Zymeworks Shares Outstanding (EOP) Historical Data

The historical data trend for Zymeworks's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Shares Outstanding (EOP) Chart

Zymeworks Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.56 46.04 46.63 63.06 70.12

Zymeworks Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.06 64.08 67.69 67.92 70.12

Competitive Comparison of Zymeworks's Shares Outstanding (EOP)

For the Biotechnology subindustry, Zymeworks's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Zymeworks's Shares Outstanding (EOP) falls into.



Zymeworks Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Zymeworks  (NAS:ZYME) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Zymeworks Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Zymeworks's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zymeworks (Zymeworks) Business Description

Traded in Other Exchanges
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Executives
Paul Andrew Moore officer: Chief Scientific Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle officer: SVP & Chief Financial Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith director, officer: Chair & CEO OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy director 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael director 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas officer: President & COO 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Troy Cox director C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton director
Kelvin Neu director 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson officer: Chief Medical Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4